Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
Still More Room To Stock Market Downside In The Coming Weeks - 23rd Sep 20
Platinum And Palladium Set To Surge As Gold Breaks Higher - 23rd Sep 20
Key Gold Ratios to Other Markets - 23rd Sep 20
Watch Before Upgrading / Buying RTX 3000, RDNA2 - CPU vs GPU Bottlenecks - 23rd Sep 20
Online Elliott Wave Markets Trading Course Worth $129 for FREE! - 22nd Sep 20
Gold Price Overboughtness Risk - 22nd Sep 20
Central Banking Cartel Promises ZIRP Until at Least 2023 - 22nd Sep 20
Stock Market Correction Approaching Initial Objective - 22nd Sep 20
Silver Bulls Will Be Handsomely Rewarded - 21st Sep 20
Fed Will Not Hike Rates For Years. Gold Should Like It - 21st Sep 20
US Financial Market Forecasts and Elliott Wave Analysis Resources - 21st Sep 20
How to Avoid Currency Exchange Risk during COVID - 21st Sep 20
Crude Oil – A Slight Move Higher Has Not Reversed The Bearish Trend - 20th Sep 20
Do This Instead Of Trying To Find The “Next Amazon” - 20th Sep 20
5 Significant Benefits of the MT4 Trading Platform for Forex Traders - 20th Sep 20
A Warning of Economic Collapse - 20th Sep 20
The Connection Between Stocks and the Economy is not What Most Investors Think - 19th Sep 20
A Virus So Deadly, The Government Has to Test You to See If You Have It - 19th Sep 20
Will Lagarde and Mnuchin Push Gold Higher? - 19th Sep 20
RTX 3080 Mania, Ebay Scalpers Crazy Prices £62,000 Trollers Insane Bids for a £649 GPU! - 19th Sep 20
A Greater Economic Depression For The 21st Century - 19th Sep 20
The United Floor in Stocks - 19th Sep 20
Mobile Gaming Market Trends And The Expected Future Developments - 19th Sep 20
The S&P 500 appears ready to correct, and that is a good thing - 18th Sep 20
It’s Go Time for Gold Price! Next Stop $2,250 - 18th Sep 20
Forget AMD RDNA2 and Buy Nvidia RTX 3080 FE GPU's NOW Before Price - 18th Sep 20
Best Back to School / University Black Face Masks Quick and Easy from Amazon - 18th Sep 20
3 Types of Loans to Buy an Existing Business - 18th Sep 20
How to tell Budgie Gender, Male or Female Sex for Young and Mature Parakeets - 18th Sep 20
Fasten Your Seatbelts Stock Market Make Or Break – Big Trends Ahead - 17th Sep 20
Peak Financialism And Post-Capitalist Economics - 17th Sep 20
Challenges of Working from Home - 17th Sep 20
Sheffield Heading for Coronavirus Lockdown as Covid Deaths Pass 432 - 17th Sep 20
What Does this Valuable Gold Miners Indicator Say Now? - 16th Sep 20
President Trump and Crimes Against Humanity - 16th Sep 20
Slow Economic Recovery from CoronaVirus Unlikely to Impede Strong Demand for Metals - 16th Sep 20
Why the Knives Are Out for Trump’s Fed Critic Judy Shelton - 16th Sep 20
Operation Moonshot: Get Ready for Millions of New COVAIDS Positives in the UK! - 16th Sep 20
Stock Market Approaching Correction Objective - 15th Sep 20
Look at This Big Reminder of Dot.com Stock Market Mania - 15th Sep 20
Three Key Principles for Successful Disruption Investors - 15th Sep 20
Billionaire Hedge Fund Manager Warns of 10% Inflation - 15th Sep 20
Gold Price Reaches $2,000 Amid Dollar Depreciation - 15th Sep 20
GLD, IAU Big Gold ETF Buying MIA - 14th Sep 20
Why Bill Gates Is Betting Millions on Synthetic Biology - 14th Sep 20
Stock Market SPY Expectations For The Rest Of September - 14th Sep 20
Gold Price Gann Angle Update - 14th Sep 20
Stock Market Recovery from the Sharp Correction Goes On - 14th Sep 20
Is this the End of Capitalism? - 13th Sep 20
The Silver Big Prize - 13th Sep 20
U.S. Shares Plunged. Is Gold Next? - 13th Sep 20
Why Are 7,500 Oil Barrels Floating on this London Lake? - 13th Sep 20
Sheffield 432 Covid-19 Deaths, Last City Centre Shop Before Next Lockdown - 13th Sep 20
Biden or Trump Will Keep The Money Spigots Open - 13th Sep 20
Gold And Silver Up, Down, Sideways, Up - 13th Sep 20

Market Oracle FREE Newsletter

How to Get Rich Investing in Stocks by Riding the Electron Wave

A Clear Way to Profit from a Graying Population

Companies / Healthcare Sector Jul 21, 2014 - 03:25 PM GMT

By: Money_Morning

Companies

Ernie Tremblay writes: The Baby Boom generation, which includes everyone born from 1946 through 1964, is now entering retirement age (65) at a rate of 10,000 per day. That demographic wave is so big that in 2010, the U.S. Administration on Aging (AoA) predicted the elderly population in this country would double to about 71 million by 2030.

That presents a huge opportunity for bioscience investors. Here's why.


As people grow older, as a group, they get sicker. About 80% of older adults cope with at least one chronic condition - illnesses that need to be managed but can't be cured - and 50% struggle with two or more. Here are some of them:

  • Alzheimer's and other dementias
  • Arthritis
  • Balance and gait problems
  • Bladder conditions
  • Cardiovascular disease
  • Cerebrovascular disease
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Depression
  • Diabetes
  • Eye disease (glaucoma, cataracts, macular degeneration)
  • High blood pressure
  • Kidney disease
  • Osteoporosis
  • Parkinson's disease
  • Prostatic hyperplasia (enlarged prostate)

Infectious diseases such as pneumonia, and injuries such as hip fractures from falling, also take a big toll on our older adults.

Naturally, the more seniors there are, the more demand there will be on the medical community for better and safer therapies to manage their health.

It's Already Happening

But that isn't the whole story. Not only are there more elders now than ever before, but they're living longer. According to the Centers for Disease Control and Prevention, life expectancy currently stands at 78.7 years for adults in the United States. Compare that to a century ago, when the average figure was 47.3 years, or a half-century ago, in 1964, when it was 70.3 years.

Thanks to advances in medicine and improved public sanitation, we've made huge strides in longevity. But the outlook isn't as rosy as the numbers suggest, because living longer means more years of dealing with those chronic conditions mentioned above.

All of this costs a lot of money. In 2010, older adults represented only 13% of the population, but accounted for 34% of total healthcare dollars spent. That's $1.3 trillion. And that's a heck of a market.

So as investors, where does all of this take us?

Obviously, with all this demand for better treatment, drugs that help manage chronic conditions associated with age will be on everyone's watch list. And they're already paying off.

Let's take a look at just one of these diseases: adult onset (type 2) diabetes.

Since the beginning of the year, MannKind Corp.'s (Nasdaq: MNKD) price per share (PPS) has risen from $5.31 to $9.70 (as I write this), an increase of more than 80%.

During that time, MNKD's new drug in development, Afrezza, an inhalable form of insulin for type 2 diabetes, received a positive recommendation from a U.S. Food and Drug Administration (FDA) advisory committee (AdCom), and then, a couple of months later, FDA approval. Predictably, both of these catalysts helped drive up PPS.

Immediately after the AdCom, PPS soared more than 100% in a single trading session.

And I suspect Afrezza won't be the last diabetes drug to deliver high profits to investors.

Opportunities Abound

In the coming months, several more new drugs will try to improve the lot of patients with diabetes, including two at opposite ends of the price spectrum...

The first, Evoke Pharma Inc. (Nasdaq: EVOK), will release data from a phase 3 trial of its experimental drug EVK-001, a potential treatment for women with recurrent diabetic gastroparesis. The data follows successful results from a previous phase 2 study of the drug.

Gastroparesis, a common side effect of diabetes, causes the stomach to take too long to empty its contents. Among its symptoms are nausea, vomiting, abdominal pain, bloating, lack of appetite, and weight loss. Up to 4% of the American population - more than 13 million people - suffer with it. A disproportionate number of them are older adults. That's a very big potential market.

Currently, EVOK is a micro cap, with a market capitalization of $42 million and a PPS in the $7 range. This stock could be a remarkable bargain for investors, but trading volume is typically low - an average of about 18,000 shares per day over three months, and currently only around 7,000. Low volume can limit buying/selling opportunities - you can't sell a stock if you can't find a buyer. Short percentage of the float is only around 7%, so the market has some confidence in the company.

The second company, GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH), is a little pricier, with a PPS around $84 and a market cap of nearly $1.5 billion. Shares currently stand at about 950% of their value one year ago.

GWPH creates, develops, and commercializes substances derived from the marijuana plant to treat disease. One of its experimental products, GWP42004, has shown very positive clinical results in a phase 2a trial for the treatment of type 2 diabetes. The company is now doing a placebo-controlled, double-blind study of the drug in diabetic patients, which should be completed by the second half of next year. I would expect successful data to drive up stock value significantly, despite the currently high price tag.

Wealth is there for the finding...

As I say, diabetes is only one example of the many age-associated conditions that will demand more and more attention from the medical research and development community over the coming decade.

There are many more golden opportunities for the investor who is willing to do a little research and find creative bioscience firms developing therapies in these areas.

And remember, these opportunities aren't limited to therapeutics. Long-term care, nursing care, in-home care, and hospice are all areas that should prove attractive to investors.

It's all just a Web search away.

Source : http://moneymorning.com/2014/07/21/a-clear-way-to-profit-from-a-graying-population/

Money Morning/The Money Map Report

©2014 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules